Pharmaceuticals, Biotechnology and Life Sciences
The Superior Court of California, County of Los Angeles rejected all but one of Gilead’s arguments to dismiss the HIV/AIDS patients’ legal theories against the company’s TDF-based HIV/AIDS drug, that cause permanent damage tokidneys and bones.
Read more
Bristol-Myers Squibb will transfer $3.8 billion of U.S. pension obligations through a full termination of its U.S. Retirement Income Plan.
Read moreM Pharmaceutical will continue develop a patented topical drug product for the treatment of female sexual dysfunction (FSD), as part
Read more
The pharmaceutical industry is typically reluctant to talk about U.S. drug prices, generally the highest in the world due to a combination of market fragmentation and free market policies. But recent high-profile price hikes by Mylan NV, Turing Pharmaceuticals and Valeant Pharmaceuticals International have raised the ire of consumers and lawmakers.
Read more
U.S. Court of Appeals for the Federal Circuit has upheld the district court’s decision and ruled in the Eli Lilly’s favor regarding validity and infringement of the vitamin regimen patent for Alimta (pemetrexed for injection).
Read more
Joseph Gunnar & Co., LLC, has exercised its over-allotment option to purchase an additional 122,500 common shares from the Akers Biosciences at $1.20 per share with the issuance of a further 61,250 warrants with an exercise price of $1.50 (the Warrants).
Read more
BioGaia has signed an exclusive agreement with Abbott for the rights to commercialize BioGaia products in the area of paediatrics and gastroenterology in Thailand.
Read more
Weifa has made a deal with New Zealand’s AFT Pharmaceuticals according to which it will sell drugs for pain relief and fever symptoms in the Nordic region (Norway, Sweden, Denmark, Finland and Iceland).
Read more
Mainstay Medical International has applied for ReActiv8 to be admitted to the Australian Register of Therapeutic Goods (ARTG) which would
Read more
U.S. President-elect Donald Trump on Wednesday said pharmaceutical companies are “getting away with murder” in what they charge the government for medicines, and promised that would change, sending drugs stocks sharply lower.
Read more